151 related articles for article (PubMed ID: 34747637)
61. Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
Lynggaard LS; Vaitkeviciene G; Langenskiöld C; Lehmann AK; Lähteenmäki PM; Lepik K; El Hariry I; Schmiegelow K; Albertsen BK
Br J Haematol; 2022 Jun; 197(6):745-754. PubMed ID: 35344210
[TBL] [Abstract][Full Text] [Related]
62. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
[TBL] [Abstract][Full Text] [Related]
63. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
Alrazzak M; Beaupin LK; Kinyoun P; Barth M
J Pediatr Hematol Oncol; 2016 Jan; 38(1):e16-20. PubMed ID: 26558809
[TBL] [Abstract][Full Text] [Related]
64. PEG-asparaginase.
Fu CH; Sakamoto KM
Expert Opin Pharmacother; 2007 Aug; 8(12):1977-84. PubMed ID: 17696798
[TBL] [Abstract][Full Text] [Related]
65. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
66. Hypoglycemia Associated With PEG-asparaginase and 6-MP Therapy During Treatment of Acute Lymphoblastic Leukemia in Pediatric Patients: A Case Series.
Jiang MR; Ahmet A; Lawrence S; Bassal M; Speckert M; Geraghty MT; Somerville S
J Pediatr Hematol Oncol; 2024 Mar; 46(2):e121-e126. PubMed ID: 38411659
[TBL] [Abstract][Full Text] [Related]
67. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
[TBL] [Abstract][Full Text] [Related]
68. The association of age and adverse events of PEG-asparaginase in a pediatric tertiary care hospital; a retrospective review.
Abbott L; Claveau M; Tang K; Cameron J; Goulet G
Eur J Haematol; 2023 Jan; 110(1):32-39. PubMed ID: 36151599
[TBL] [Abstract][Full Text] [Related]
69. Pegylated asparaginase as cause of fatal hyperammonemia in patients with latent urea cycle disorder.
Peters M; Zee-Cheng J; Kuhl A; Orozco J; Lally E; Schwoerer JS
Pediatr Blood Cancer; 2018 Sep; 65(9):e27239. PubMed ID: 29775236
[No Abstract] [Full Text] [Related]
70. Epidural hematoma in a patient on pegylated-L-asparginase therapy.
Qubty WF; Mrelashvili A; Patterson MC
J Child Neurol; 2015 Apr; 30(5):636. PubMed ID: 24396128
[No Abstract] [Full Text] [Related]
71. Asparaginase allergies: it's all in the genes.
Wetzler M
Blood; 2014 Aug; 124(8):1206-7. PubMed ID: 25147374
[TBL] [Abstract][Full Text] [Related]
72. Different profile of thrombin generation in children with acute lymphoblastic leukaemia treated with native or pegylated asparaginase: A cohort study.
Rozen L; Noubouossie D; Dedeken L; Huybrechts S; Lê PQ; Ferster A; Demulder A
Pediatr Blood Cancer; 2017 Feb; 64(2):294-301. PubMed ID: 27605400
[TBL] [Abstract][Full Text] [Related]
73. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
74. From the Children's Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education.
Woods D; Winchester K; Towerman A; Gettinger K; Carey C; Timmermann K; Langley R; Browne E
J Pediatr Oncol Nurs; 2017; 34(6):387-396. PubMed ID: 28602129
[TBL] [Abstract][Full Text] [Related]
75. Reply to: Comment on: Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.
Hasan H; Shaikh OM; Rassekh SR; Howard AF; Goddard K
Pediatr Blood Cancer; 2018 Aug; 65(8):e27106. PubMed ID: 29693786
[No Abstract] [Full Text] [Related]
76. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Salzer WL; Asselin B; Supko JG; Devidas M; Kaiser NA; Plourde P; Winick NJ; Reaman GH; Raetz E; Carroll WL; Hunger SP
Blood; 2013 Jul; 122(4):507-14. PubMed ID: 23741010
[TBL] [Abstract][Full Text] [Related]
77. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
78. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
[No Abstract] [Full Text] [Related]
79. A desensitization protocol in children with L-asparaginase hypersensitivity.
Akbayram S; Doğan M; Akgün C; Caksen H; Oner AF
J Pediatr Hematol Oncol; 2010 Jul; 32(5):e187-91. PubMed ID: 20505537
[TBL] [Abstract][Full Text] [Related]
80. Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice.
Rathod S; Ramsey M; Finkelman FD; Fernandez CA
Blood Adv; 2020 Sep; 4(18):4406-4416. PubMed ID: 32931581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
